COST-OF-ILLNESS OF PNEUMONIA, BACTEREMIA OR MENINGITIS IN COLOMBIAN ADULTS: A RETROSPECTIVE DATABASE STUDY, 2015 TO 2022
Author(s)
Jair A. Arciniegas, MSc1, Juan Manuel Reyes, MSc1, Jhon Edwar Bolaños, MSc, MD2, Andreina Jose Alamo, BSc1, Carlos Bello, MSc2, Mónica García, MSc1, Luz Eugenia Perez Jaramillo, MD, MSc2, Farley J. Gonzalez, MD MSc2, Jose Oñate, MD2, Omar Escobar, MD MSc1, Jennifer Onwumeh-Okwundu, MD MSc3, Jorge LaRotta, MD1, Mark A. Fletcher, MD4.
1Pfizer SAS, Bogotá, Colombia, 2SURA, Medellín, Colombia, 3Pfizer, Tennessee, TN, USA, 4Pfizer, Paris, France.
1Pfizer SAS, Bogotá, Colombia, 2SURA, Medellín, Colombia, 3Pfizer, Tennessee, TN, USA, 4Pfizer, Paris, France.
Presentation Documents
OBJECTIVES: To describe the direct medical cost of pneumonia, bacteremia, or meningitis of adult patients in a health maintenance organization (HMO) in Colombia.
METHODS: This observational study included adult patients with healthcare resource data available who were diagnosed, without a documented etiology, as pneumonia, bacteremia, or meningitis—conditions arranged using International Classification of Diseases 10th Edition (ICD-10) codes—receiving care from the HMO services between 2015 and 2022. The study sourced the healthcare resource consumption from the electronic health records; costs were calculated using national databases. Costs were adjusted to 2025 and converted to US dollars using an exchange rate of 3804.09 COP=1 USD.
RESULTS: A total of 81,238 patients, median age of 53 years and 58.5% female, presented with a median value of 2 comorbidities, and 60.1% had been diagnosed before 2020. Over 90% were pneumonia cases, primarily treated as outpatients (n=61,519), while 18.7% were managed by the inpatient services. Approximately 8.6% were bacteremia, and less than 1% (n=412) had meningitis. Inpatient pneumonia cases posed the largest total cost at $130,687,036 USD, followed by bacteremia cases ($53,409,057), meningitis cases ($2,385,970), and outpatient pneumonia cases ($1,859,643). The median cost per case diverged substantially by age between those under 50 years and those aged 50 and over: for meningitis cases the difference between these groups was $686.3 median cost (<50 = $2,573.9 vs. ≥50 = $3,260.2), for bacteremia cases the difference was $365.2 (<50 =$ 2,253.2 vs. ≥50 = $2,618.4), while for inpatient pneumonia cases this difference was $320.7 (<50 = $1,932.5 vs ≥50 = $2,253.2). But for outpatient pneumonia cases it was $5.1 (<50 = $16 vs. ≥50 = $21.1).
CONCLUSIONS: The median cost per clinical case was larger for the older age group for each diagnosis. Overall, inpatient pneumonia cases caused the largest economic impact despite only representing one-fifth of the total cases.
METHODS: This observational study included adult patients with healthcare resource data available who were diagnosed, without a documented etiology, as pneumonia, bacteremia, or meningitis—conditions arranged using International Classification of Diseases 10th Edition (ICD-10) codes—receiving care from the HMO services between 2015 and 2022. The study sourced the healthcare resource consumption from the electronic health records; costs were calculated using national databases. Costs were adjusted to 2025 and converted to US dollars using an exchange rate of 3804.09 COP=1 USD.
RESULTS: A total of 81,238 patients, median age of 53 years and 58.5% female, presented with a median value of 2 comorbidities, and 60.1% had been diagnosed before 2020. Over 90% were pneumonia cases, primarily treated as outpatients (n=61,519), while 18.7% were managed by the inpatient services. Approximately 8.6% were bacteremia, and less than 1% (n=412) had meningitis. Inpatient pneumonia cases posed the largest total cost at $130,687,036 USD, followed by bacteremia cases ($53,409,057), meningitis cases ($2,385,970), and outpatient pneumonia cases ($1,859,643). The median cost per case diverged substantially by age between those under 50 years and those aged 50 and over: for meningitis cases the difference between these groups was $686.3 median cost (<50 = $2,573.9 vs. ≥50 = $3,260.2), for bacteremia cases the difference was $365.2 (<50 =$ 2,253.2 vs. ≥50 = $2,618.4), while for inpatient pneumonia cases this difference was $320.7 (<50 = $1,932.5 vs ≥50 = $2,253.2). But for outpatient pneumonia cases it was $5.1 (<50 = $16 vs. ≥50 = $21.1).
CONCLUSIONS: The median cost per clinical case was larger for the older age group for each diagnosis. Overall, inpatient pneumonia cases caused the largest economic impact despite only representing one-fifth of the total cases.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD45
Topic
Real World Data & Information Systems
Disease
SDC: Infectious Disease (non-vaccine)